Welcome to our dedicated page for Neuphoria Therapeutics SEC filings (Ticker: NEUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 250-page biotech filing can feel like decoding lab notes. Neuphoria Therapeutics’ SEC documents dive deep into clinical-trial data, cash runway projections, and dilution risks that matter to every biotech investor. If you have ever asked, “Where can I find Neuphoria Therapeutics’ quarterly earnings report 10-Q filing?” or searched for “Neuphoria Therapeutics insider trading Form 4 transactions,” you already know how scattered EDGAR can be.
Stock Titan solves that problem. Our AI reads each 10-K, 10-Q, and 8-K the moment it hits EDGAR, then delivers plain-English summaries so you can focus on BNC210 trial timelines, partnership milestones, or financing covenants without wading through dense pharmacology. Need Form 4 alerts? We stream Neuphoria Therapeutics Form 4 insider transactions real-time and flag patterns in executive stock transactions Form 4 filings. Want context? Our platform links every footnote to an explanation, turning “understanding Neuphoria Therapeutics SEC documents with AI” from wishful thinking into a two-minute read.
Whether you’re gauging dilution risk through an annual report 10-K simplified, looking for proxy statement executive compensation details, or checking a sudden 8-K material events explained, you’ll find it here. Investors routinely use our earnings report filing analysis to spot R&D expense trends, compare burn rate quarter-over-quarter, and monitor compliance triggers before they affect valuation. All filings, all the time—kept current with real-time updates and backed by expert narrative so Neuphoria Therapeutics SEC filings are explained simply.
Neuphoria Therapeutics insider filing: Spyros Papapetropoulos, President, CEO and director of Neuphoria Therapeutics (NEUP), reported an option grant on 08/27/2025 for 34,559 employee stock options with an exercise price of $8.27 per share. The options vest monthly over four years beginning August 1, 2025, at a rate of 2.0833% of the shares on the last day of each month, and expire on 08/27/2035. After the grant, the reporting person beneficially owns 74,088 shares of common stock directly. The Form 4 was signed on 09/01/2025.
FAQ
What is the current stock price of Neuphoria Therapeutics (NEUP)?
What is the market cap of Neuphoria Therapeutics (NEUP)?
